MarketLens

Log in

What Do Recent Congressional Trades Signal for Workday (WDAY)

3 hours ago
SHARE THIS ON:

What Do Recent Congressional Trades Signal for Workday (WDAY)

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News1 day ago

Senator Buys Up Consumer Staples: Here's Two Stocks On The Shopping List

A U.S. senator recently disclosed the purchase of two consumer staples stocks, drawing attention from retail investors who monitor congressional trading activity. The disclosure highlights specific in...
Stock News1 week ago

The One Number That Could Break NANC's AI Rally in 2026

The Unusual Whales Subversive Democratic Trading ETF (NANC) tracks congressional stock disclosures filed under the STOCK Act. Investors monitor these 45-day delayed filings to identify potential infor...
Stock News1 week ago

Investors Heavily Search Workday, Inc. (WDAY): Here is What You Need to Know

Workday (WDAY) has experienced a recent surge in investor interest on Zacks.com. This heightened attention highlights the need for market participants to evaluate the company's fundamental prospects a...
Stock News2 weeks ago

Occidental Petroleum Corp WT (NYSE:OXY.W) Trading Down 2.3% – What’s Next?

Occidental Petroleum Corp warrants (OXY.W) fell 2.3% to $34.96 during Friday's mid-day session. Trading volume reached ~36,365 shares, representing a 73% decline from the 134,776-share average daily v...

Breaking News

View All →

Top Headlines

View More →
Stock News48 minutes ago

Meta challenges New Mexico's $3.7 billion plan for teen mental health in social media trial

Stock News57 minutes ago

Instagram Introduces Instants, Meta's New Private Photo Sharing App

Stock News1 hour ago

Nvidia (NVDA) Exceeds Market Returns: Some Facts to Consider

Stock News1 hour ago

Apple Prepares App Store for Autonomous AI Agents

Stock News1 hour ago

Isomorphic Labs' $2.1 Billion Fundraise Is The Biggest Bet Yet On AI Drug Discovery